Close Menu

MIT

In Cell this week: strategies for targeting leukemia with MLL translocations, new Perturb-seq approach, and more.

The licenses cover IP related to a new CRISPR technology known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.

Two Broad Institute teams, led by Eric Lander and Feng Zhang, respectively, have published new papers today in Science on new uses for lenti-CRISPR screens.

Researchers are making mutations in a cell's genome to mark it and later read out that information to create cell lineage maps and chemical interaction histories.

The method works by adding noise to database search results to confound algorithms that try to access private details about contributing individuals.

The Food Allergy Science Initiative seeks to supply the basic scientific research needed to spur future development of diagnostics and therapeutics.

Discovered and characterized through a collaboration between Feng Zhang's lab and the NCBI, C2c2 opens up the RNA world to editing and other applications.

Its first client, Haystack Bio, will use Genecloud to analyze and store single-cell genomics data for a proprietary platform it is developing for the immunotherapy market.

Researchers led by MIT's Jim Collins have built upon their paper-based Ebola test and are hoping to find a partner to help scale production and manufacturing of the test.

Tech-Transfer Maven

Lita Nelsen from the Massachusetts Institute of Technology's technology-transfer office is retiring after decades there.

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.